Patent ID: 7262223
Filing Date: 2007-08-28
Classification: A61K

Abstract:
1. A method of treating a disease selected from the group consisting of Alzheimer's disease, Down's syndrome, Mild Cognitive Impairment, age-related macular degeneration, and cerebral amyloid angiopathy in a subject in need thereof comprising administering to a subject a therapeutically effective amount of a compound, wherein said compound is selected from the group consisting of N-(6-aminoheptyl)-4-bromobenzamidine (compound #145), 4-bromo-N-{7-[(4-bromobenzimidoyl)-amino]-heptyl}-benzamide (compound #146), N-hydroxy-4-(9-hydroxyaminononyloxy)-benzamidine (compound #147), N-[7-(4-carbamimidoylbenzoylamino)-heptyl]-terephthalamic acid ethyl ester (compound #148), N-[9-(4-carbamimidoyl-benzoylamino)-nonyl]-terephthalamic acid ethyl ester (compound #149), 4,4′-(pentamethylenediamidino)di(p-bromobenzene) (compound #150), 4,4′-(nonamethylenediamidino)di(p-bromobenzene) (compound #151), 4,4′-(nonamethylenediamidino)di(p-methoxybenzene) (compound #152), 4-methoxy-N-{2-[2-(4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-ethyl}-benzamidine (compound #153), 4,4′-(pentamethylenediamidino)di(p-methoxybenzene) (compound #154), 2,2′-(p-amidinophenylcarboxamido)-N,N-diethyl-p-amidinobenzamide (compound #155), {4-[5-(p-aminophenoxy)-pentyloxy]-phenyl}-(4,5-dihydro-1H-imidazol-2-yl)-amine (compound #156), 4,4′-(nonamethylenedisulfamyl)di(amidinobenzene) (compound #158), 3,3′-(pentamethylenediaminocarbonyl)di(amidinobenzene) (compound #159), 4,4′-(tetramethylenediaminocarbonyl)di(amidinobenzene) (compound #160), and pharmaceutically acceptable salts thereof.